PAVM · Pavmed Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.0K | - | $5.0K | $6.0K | $8.0K | - | $1.00M | $1.00M | $1.01M | - |
| Cost of Revenue | $97.0K | - | $55.0K | $41.0K | $36.0K | - | $1.38M | $1.67M | $1.74M | - |
| Gross Profit | ($75.0K) | - | ($50.0K) | ($35.0K) | ($28.0K) | - | ($381.0K) | ($666.0K) | ($734.0K) | - |
| R&D | $1.39M | - | $1.09M | $790.0K | $787.0K | - | $1.54M | $1.64M | $1.94M | - |
| SG&A | $6.36M | - | $3.50M | $3.67M | $4.38M | - | $6.65M | $7.01M | $6.68M | - |
| Total Operating Expenses | $8.06M | - | $4.85M | $4.72M | $5.45M | - | $12.57M | $14.66M | $15.05M | - |
| D&A | $20.0K | - | - | - | $43.0K | - | - | - | $586.0K | - |
| Operating Income | ($8.04M) | - | ($4.84M) | ($4.71M) | ($5.45M) | - | ($11.58M) | ($13.68M) | ($14.04M) | - |
| Interest Expense | $3.0K | - | $8.0K | $26.0K | $26.0K | - | $12.0K | $11.0K | $16.0K | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - |
| Net Income | ($60.0K) | - | ($5.38M) | ($11.92M) | $18.97M | - | $64.40M | ($10.83M) | ($15.21M) | - |
| EPS - Basic | ($4.42) | - | ($0.29) | ($1.19) | $1.28 | - | $6.43 | - | ($2.62) | - |
| EPS - Diluted | ($4.42) | - | ($0.29) | ($0.74) | $0.34 | - | $1.44 | ($1.19) | ($2.62) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.46M | $1.54M | $3.10M | $4.00M | $2.70M | $1.19M | $765.0K | $25.50M | $25.54M | $19.64M |
| Accounts Receivable | $21.0K | $15.0K | $3.0K | $3.0K | $9.0K | $18.0K | $16.0K | $219.0K | $67.0K | $61.0K |
| Inventory | - | - | - | - | - | - | $6.0K | $687.0K | $410.0K | $278.0K |
| Accounts Payable | $983.0K | $678.0K | $342.0K | $387.0K | $369.0K | $657.0K | $465.0K | $1.23M | $1.49M | $1.79M |
| Current Assets | $7.41M | $2.56M | $4.19M | $5.49M | $3.64M | $2.16M | $2.13M | $30.21M | $29.57M | $24.50M |
| Total Assets | $45.42M | $38.81M | $38.07M | $43.89M | $52.82M | $30.66M | $30.55M | $39.41M | $37.25M | $33.12M |
| Current Liabilities | $3.66M | $14.84M | $10.46M | $10.51M | $9.78M | $35.45M | $37.56M | $53.39M | $55.02M | $54.18M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $20.43M | $16.51M | $12.28M | $12.47M | $11.89M | $37.69M | $39.94M | $58.05M | $57.83M | $57.14M |
| Stockholders' Equity | $39.52M | $33.97M | $32.52M | $37.53M | $44.99M | ($2.50M) | ($4.87M) | ($73.94M) | ($68.78M) | ($53.83M) |
| Retained Earnings | ($259.03M) | ($258.73M) | ($256.90M) | ($250.57M) | ($237.27M) | ($254.97M) | ($256.31M) | ($320.63M) | ($309.72M) | ($294.43M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.62M) | - | - | - | ($1.58M) | - | - | - | ($13.11M) | - |
| Investing Cash Flow | ($22.0K) | - | - | - | ($6.0K) | - | - | - | ($42.0K) | - |
| Financing Cash Flow | $7.56M | - | - | - | $3.10M | - | - | - | $19.05M | - |
| CapEx | $22.0K | - | - | - | $6.0K | - | - | - | $42.0K | - |
| Free Cash Flow | ($2.64M) | - | - | - | ($1.59M) | - | - | - | ($13.15M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | -340.9% | - | -1000.0% | -583.3% | -350.0% | - | -38.1% | -66.6% | -72.7% | - |
| Operating margin | -36522.7% | - | -96880.0% | -78583.3% | -68075.0% | - | -1157.8% | -1368.4% | -1389.7% | - |
| EBITDA margin | -36431.8% | - | - | - | -67537.5% | - | - | - | -1331.7% | - |
| Net margin | -272.7% | - | -107660.0% | -198683.3% | 237100.0% | - | 6439.9% | -1082.7% | -1506.1% | - |
| Free cash flow margin | -12009.1% | - | - | - | -19837.5% | - | - | - | -1302.1% | - |
| FCF / Net income | 44.03 | - | - | - | -0.08 | - | - | - | 0.86 | - |
| R&D / Revenue | 6309.1% | - | 21760.0% | 13166.7% | 9837.5% | - | 154.2% | 164.1% | 192.2% | - |
| SG&A / Revenue | 28890.9% | - | 70100.0% | 61166.7% | 54800.0% | - | 664.9% | 700.9% | 661.2% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -0.1% | - | -14.1% | -27.2% | 35.9% | - | 210.8% | -27.5% | -40.8% | - |
| Return on equity | -0.2% | - | -16.6% | -31.8% | 42.2% | - | -1322.6% | 14.6% | 22.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.02 | 0.17 | 0.40 | 0.52 | 0.37 | 0.06 | 0.06 | 0.57 | 0.54 | 0.45 |
| Quick ratio | 2.02 | 0.17 | 0.40 | 0.52 | 0.37 | 0.06 | 0.06 | 0.55 | 0.53 | 0.45 |
| Cash ratio | 1.76 | 0.10 | 0.30 | 0.38 | 0.28 | 0.03 | 0.02 | 0.48 | 0.46 | 0.36 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -2678.3x | - | -605.5x | -181.3x | -209.5x | - | -964.8x | -1244.0x | -877.3x | - |
| Equity multiplier | 1.15 | 1.14 | 1.17 | 1.17 | 1.17 | -12.29 | -6.27 | -0.53 | -0.54 | -0.62 |
| Liabilities / Assets | 0.45 | 0.43 | 0.32 | 0.28 | 0.23 | 1.23 | 1.31 | 1.47 | 1.55 | 1.73 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.03 | 0.03 | 0.03 | - |
| Inventory turnover | - | - | - | - | - | - | 230.17 | 2.43 | 4.25 | - |
| Days sales outstanding | 348d | - | 219d | 183d | 411d | - | 6d | 80d | 24d | - |
| Days inventory outstanding | - | - | - | - | - | - | 2d | 151d | 86d | - |
| Days payable outstanding | 3699d | - | 2270d | 3445d | 3741d | - | 123d | 270d | 311d | - |
| Cash conversion cycle | - | - | - | - | - | - | -115d | -39d | -201d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 175.0% | - | -99.5% | -99.4% | -99.2% | - | 26.4% | 502.4% | 126.5% | - |
| Revenue CAGR (3y) | -63.3% | - | -59.6% | - | -65.1% | - | 71.0% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -167.9% | - | 86.9% | 94.7% | 96.2% | - | 61.4% | - | 18.4% | - |
| Operating income growth (YoY) | -47.5% | - | 58.2% | 65.5% | 61.2% | - | 25.4% | 17.0% | 31.2% | - |
| Net income growth (YoY) | - | - | - | -10.1% | - | - | - | 25.5% | 15.2% | - |
| EPS growth (YoY) | - | - | - | 37.8% | - | - | - | -750.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -66.5% | - | - | - | 87.9% | - | - | - | 19.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -12.2% | - | - | - | - | 95.4% | 88.7% | -134.7% | -211.8% | -456.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$100.00M totalRoyalty$100.00M · 100.0%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing PAVmed Inc. against the 5 most active filers in the same SIC group.